The initiative reported here is among the first to investigate the barriers to wider application of CGM in UK general practice, specifically for individuals with T2D on non‐intensive insulin therapy, and the opportunities provided by successfully implementation. This evidence concerns the gene INS and type 2 diabetes mellitus.